Cart
sales@molnova.com
Hederagenin 3-O-(2-O-acetyl-alpha-L-arabinopyranoside)
CAS No. 87562-05-8
Hederagenin 3-O-(2-O-acetyl-alpha-L-arabinopyranoside)( —— )
Catalog No. M32295 CAS No. 87562-05-8
Hederagenin 3-O-(2-O-acetyl-α-L-arabinopyranoside) significantly increased alkaline phosphatase (ALP) activity and the level of protein expression of bone sialoprotein (BSP) and osteocalcin (OC) .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 551 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHederagenin 3-O-(2-O-acetyl-alpha-L-arabinopyranoside)
-
NoteResearch use only, not for human use.
-
Brief DescriptionHederagenin 3-O-(2-O-acetyl-α-L-arabinopyranoside) significantly increased alkaline phosphatase (ALP) activity and the level of protein expression of bone sialoprotein (BSP) and osteocalcin (OC) .
-
DescriptionHederagenin 3-O-(2-O-acetyl-α-L-arabinopyranoside) significantly increased alkaline phosphatase (ALP) activity and the level of protein expression of bone sialoprotein (BSP) and osteocalcin (OC) .
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number87562-05-8
-
Formula Weight646.9
-
Molecular FormulaC37H58O9
-
Purity>98% (HPLC)
-
SolubilityDMSO, Pyridine, Methanol, Ethanol, etc.
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Glucomoringin
The seeds of Sinapis alba L.
-
Lixisenatide
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).It is an injectable diabetes medicine that helps control blood sugar levels.
-
RMC-7977
RMC-7977 is a highly selective inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS with anticancer activity for the study of solid tumors with KRAS G12C mutations.
